Related by context. All words. (Click for frequent words.) 72 chronic lymphocytic leukemia CLL 68 NSCLC 67 DLBCL 66 glioblastoma 66 follicular lymphoma 66 multiple myeloma 65 metastatic renal cell carcinoma 64 renal cell carcinoma 64 advanced NSCLC 64 lymphomas 64 leukemia CLL 63 metastatic colorectal cancer 63 non Hodgkin lymphoma 63 indolent NHL 62 metastatic melanoma 62 chronic lymphocytic leukemia 62 hepatocellular carcinoma HCC 61 acute myeloid leukemia AML 61 chronic myeloid leukemia CML 61 HER2 positive breast cancer 61 rituximab 61 relapsed refractory 61 cell lung cancer 61 Non Hodgkin Lymphoma 61 acute myeloid leukemia 61 GIST 61 HCV infection 61 solid tumors 60 Non Hodgkin lymphoma 60 CTCL 60 bortezomib 60 non Hodgkin lymphomas 59 B CLL 59 leukemia ALL 59 acute myelogenous leukemia AML 59 medulloblastoma 59 hepatocellular carcinoma 59 cell lymphoma 59 cell lymphomas 59 carcinoma 59 neuroendocrine tumors 59 multiple myeloma MM 59 melanoma 58 castration resistant prostate cancer 58 pancreatic adenocarcinoma 58 sorafenib 58 Gleevec resistant 58 Pixantrone 58 chemotherapy regimens 58 HER2 positive metastatic breast 58 leukemia AML 58 metastatic RCC 58 malignant pleural mesothelioma 58 metastatic cancer 58 metastatic breast cancer 57 myelofibrosis 57 Chronic Lymphocytic Leukemia CLL 57 gastric cancer 57 CLL SLL 57 imatinib resistant 57 sunitinib 57 acute leukemias 57 cell malignancies 57 lupus nephritis 57 gastrointestinal stromal tumors 57 lymphoma 57 HRPC 57 HCV 57 malignancies 57 dasatinib 57 mRCC 57 lymphoma CTCL 57 Burkitt lymphoma 57 Acute Myelogenous Leukemia AML 57 cutaneous T cell 57 Follicular lymphoma 57 chronic myeloid leukemia 57 glioblastoma multiforme GBM 56 metastatic disease 56 recurrent NSCLC 56 hematological cancers 56 disease progression 56 heavily pretreated 56 acute lymphoblastic leukemia 56 basal cell carcinoma BCC 56 hormone refractory prostate cancer 56 erlotinib 56 HER2 positive 56 myelodysplastic syndrome MDS 56 metastatic prostate cancer 56 bendamustine 56 hematologic malignancies 56 axitinib 56 chronic myelogenous leukemia CML 56 mCRC 56 lumiliximab 56 ofatumumab 56 relapsing remitting multiple sclerosis 56 systemic lupus erythematosus 56 prostate cancer CRPC 56 Hodgkin lymphoma NHL 55 small lymphocytic lymphoma 55 leukemias 55 brain metastases 55 carcinoid tumors 55 medullary thyroid cancer 55 cell lymphoma CTCL 55 cancers 55 malignant melanoma 55 imatinib 55 lymphocytic leukemia 55 leukaemias 55 refractory multiple myeloma 55 non Hodgkin Lymphoma 55 pancreatic carcinoma 55 pancreatic NET 55 Rituxan 55 Alemtuzumab 55 IMGN# 55 rheumatoid arthritis RA 55 gastrointestinal stromal tumor GIST 55 metastatic 55 Imatinib 55 mycosis fungoides 55 Chronic lymphocytic leukemia 55 Rituximab 55 stage IIIB 55 colorectal cancer 55 glioblastoma multiforme 54 hematologic disorders 54 Acute Myeloid Leukemia AML 54 gastrointestinal stromal tumor 54 T#I mutation 54 acute promyelocytic leukemia 54 EGFR mutations 54 CHOP chemotherapy 54 Mantle Cell Lymphoma 54 prostate cancers 54 superficial bladder cancer 54 myelodysplastic syndromes MDS 54 Glioblastoma 54 Non Hodgkin 54 CD# [002] 54 hepatocellular cancer 54 metastatic colon cancer 54 recurrent ovarian cancer 54 glioma 54 resistant ovarian cancer 54 nilotinib 54 gefitinib 54 imatinib Gleevec 54 liver metastases 54 panobinostat 54 metastatic malignant melanoma 54 recurrent glioblastoma 54 differentiated thyroid 54 histologies 54 cetuximab 54 Myelodysplastic Syndrome MDS 54 AML 54 alemtuzumab 54 HNSCC 54 Fludarabine 54 tyrosine kinase inhibitors 54 liver cancer 54 cytotoxic chemotherapy 54 gefitinib Iressa 54 Ofatumumab 54 lapatinib 54 Ceflatonin 54 hematological malignancy 53 relapsing remitting 53 hematological malignancies 53 relapsed CLL 53 azacitidine 53 diabetic nephropathy 53 acute leukemia 53 imatinib mesylate 53 colorectal cancer CRC 53 refractory CLL 53 indolent lymphoma 53 Glioblastoma Multiforme 53 GvHD 53 TKI therapy 53 Fludara 53 glioblastomas 53 myelodysplastic syndromes 53 systemic lupus erythematosus SLE 53 EGFR inhibitors 53 pleural mesothelioma 53 Rituxan rituximab 53 Crohn disease 53 recurrent GBM 53 MALT lymphoma 53 gliomas 53 relapsing multiple sclerosis 53 bladder cancer 53 OMAPRO 53 Waldenstrom macroglobulinemia 53 Cutaneous T 53 Diffuse Large B 53 Lymphoma 53 myeloma 53 chronic HCV 53 pancreatic neuroendocrine tumors 53 relapsed ovarian cancer 53 anti angiogenic therapy 53 imatinib therapy 53 Hodgkin lymphoma HL 53 imatinib Gleevec ® 53 soft tissue sarcomas 53 Epratuzumab 53 metastatic malignant 53 WT1 53 BRAF mutation 53 Bortezomib 53 medulloblastomas 53 platinum refractory 53 follicular lymphoma FL 53 IV NSCLC 53 Myelofibrosis 53 Hodgkin Lymphoma 53 IV metastatic melanoma 53 tumors 53 TREANDA 53 anti TNF 53 vandetanib 53 PCa 53 myelodysplastic syndrome 52 previously untreated follicular 52 essential thrombocythemia 52 chlorambucil 52 trabectedin 52 temsirolimus 52 bone metastasis 52 relapsed leukemia 52 prostate cancer CaP 52 nonsmall cell lung cancer 52 Ilaris 52 Gleevec imatinib mesylate 52 leukemia 52 YONDELIS 52 Torisel 52 Clolar 52 unresectable 52 relapsed multiple myeloma 52 Cholangiocarcinoma 52 decitabine 52 biologic therapy 52 cytogenetic responses 52 enzastaurin 52 metastatic renal cell 52 haematological malignancies 52 HuMax CD4 52 HDACi 52 adenocarcinoma 52 bevacizumab Avastin ® 52 cell carcinoma 52 malignancy 52 Amrubicin 52 relapsed SCLC 52 gastric cancers 52 Follicular Lymphoma 52 docetaxel 52 Non Hodgkins Lymphoma 52 perifosine 52 sorafenib Nexavar 52 cell lymphoma DLBCL 52 refractory ovarian cancer 52 hepatitis C genotype 52 MabThera 52 HCV infections 52 pazopanib 52 severe sepsis 52 EGFr 52 Dasatinib 52 cutaneous melanoma 52 Erlotinib 52 gastrointestinal stromal tumors GIST 52 neuroblastoma 52 sporadic ALS 52 indolent lymphomas 52 ipilimumab 52 fludarabine 52 refractory NSCLC 52 FTLD 52 topotecan 52 cell acute lymphoblastic 52 IV melanoma 52 rituximab refractory 52 malignant mesothelioma 52 trastuzumab 52 standard chemotherapy regimen 52 chronic myelogenous leukemia 52 KRAS 52 bone metastases 52 follicular NHL 52 T#I [002] 52 gastrointestinal cancers 52 Acute Lymphoblastic Leukemia 52 familial amyloidotic polyneuropathy FAP 52 metastases 52 SCCHN 52 lymphoblastic leukemia 52 abiraterone 52 seminoma 52 Chronic Myeloid Leukaemia 51 lung tumors 51 non metastatic osteosarcoma 51 refractory chronic myeloid 51 Myelodysplastic Syndrome 51 lymphoid malignancies 51 non squamous NSCLC 51 Friedreich ataxia 51 ZEVALIN 51 Leukemias 51 liver fibrosis 51 clusterin 51 squamous cell carcinoma 51 relapsed refractory multiple myeloma 51 Acute myeloid leukemia 51 myeloproliferative neoplasms 51 neoadjuvant treatment 51 obatoclax 51 vinorelbine 51 PARP inhibitors 51 colon carcinoma 51 Treanda 51 PsA 51 follicular lymphomas 51 pomalidomide 51 EGFR 51 PLX# 51 Hodgkin lymphoma 51 sarcoma 51 Metastatic Colorectal Cancer 51 acute promyelocytic leukemia APL 51 chemotherapeutic agent 51 hypomethylating agents 51 heavily pretreated patients 51 stage IIIB IV 51 prostate cancer 51 FLT3 51 GISTs 51 haematologic malignancies 51 gemcitabine 51 candidemia 51 Acute Myeloid Leukemia 51 DMARDs 51 Pemetrexed 51 relapsing remitting MS 51 cutaneous T 51 Chronic Myeloid Leukemia 51 prostate adenocarcinoma 51 HGS ETR1 51 clofarabine 51 carfilzomib 51 MGUS 51 Aplidin 51 bevacizumab Avastin 51 relapsed AML 51 squamous cell carcinoma SCC 51 myeloid 51 oral fludarabine 51 Herceptin trastuzumab 51 ependymoma 51 Velcade bortezomib 51 ASA# 51 cisplatin 51 metastatic kidney 51 dasatinib Sprycel 51 GVHD 51 EGFR mutation 51 Doxil ® 51 Vectibix 51 Campath alemtuzumab 51 metastatic cancers 51 Hepatocellular Carcinoma HCC 51 breast carcinomas 51 romidepsin 51 Chronic Myeloid Leukemia CML 51 mutated KRAS gene 51 ZACTIMA 51 relapsed GBM 51 metastatic CRC 51 GBM tumors 51 anthracyclines 51 systemic ALCL 51 bleomycin 51 erlotinib Tarceva ® 51 familial ALS 51 CRPC 51 pancreatic cancer 51 K ras mutations 51 follicular non 51 cilengitide 51 anticancer therapy 51 bladder cancers 51 cancer mCRC 51 chemoradiation 51 COPD 51 refractory indolent non 51 FOLFIRI 51 chemoradiotherapy 51 interferon 51 depsipeptide 51 HER2 overexpression 51 alkylating agent 51 metastatic lung cancer 51 idiopathic pulmonary fibrosis IPF 51 VZV 50 HSCT 50 vemurafenib 50 abiraterone acetate 50 Acute lymphoblastic leukemia 50 BCR ABL 50 elacytarabine 50 milatuzumab 50 cell lymphoma MCL 50 chemotherapeutic agents 50 Relapsed Refractory 50 advanced hepatocellular carcinoma 50 recurrent glioblastoma multiforme 50 TroVax 50 angiogenesis inhibition 50 CLL cells 50 hormone refractory 50 metastatic pancreatic cancer 50 Zolinza 50 PKCi 50 Sutent 50 HCV genotype 1 50 scleroderma 50 neoplasia 50 standard chemotherapy regimens 50 JAK2 inhibitors 50 docetaxel chemotherapy 50 metastatic hormone refractory 50 HER2 50 squamous 50 chronic ITP 50 Rituxan MabThera 50 PXD# 50 SUTENT 50 Clofarabine 50 idarubicin 50 grade gliomas 50 SHPT 50 pediatric acute lymphoblastic 50 recurrent glioma 50 ovarian cancer 50 hepatitis C HCV 50 cell lymphoma ALCL 50 prostate cancer mCRPC 50 Gleevec 50 breast tumors 50 unresectable stage 50 AA amyloidosis 50 Sorafenib 50 tocilizumab 50 phenoxodiol 50 metastatic gastric 50 colorectal cancers 50 K ras 50 mapatumumab 50 sarcomas 50 advanced metastatic renal 50 nonmetastatic 50 carcinomas 50 atypical hemolytic uremic syndrome 50 carcinoid 50 synovial sarcoma 50 Acute Myelogenous Leukemia 50 basal cell carcinomas 50 CMV disease 50 invasive candidiasis 50 neoadjuvant chemotherapy 50 thymoma 50 Chronic Lymphocytic Leukemia 50 castrate resistant prostate cancer 50 chemotherapy regimen 50 Acute Coronary Syndromes ACS 50 malignant gliomas 50 panitumumab 50 haematological cancers 50 T DM1 50 Carboplatin 50 sorafenib Nexavar ® 50 refractory chronic lymphocytic 50 dasatinib Sprycel ® 50 pixantrone 50 chronic hepatitis C. 50 relapsed Hodgkin lymphoma 50 soft tissue sarcoma 50 ADVEXIN 50 trans retinoic acid 50 Trastuzumab 50 lymphoma subtypes 50 vWD 50 KRAS wild 50 NPM1 50 EpCAM 50 MabCampath 50 mCRC patients 50 EOquin 50 tumor recurrence 50 ErbB2 positive 50 HBeAg positive 50 histologically confirmed 50 ovarian carcinoma 50 kinase inhibitor 50 metastatic GIST 50 azacytidine 50 tumor progression 50 Xanafide 50 cetuximab Erbitux R 50 velaglucerase alfa 50 elotuzumab 50 pegylated liposomal doxorubicin 50 EGFR tyrosine kinase inhibitors 50 HCV infected 50 anaplastic 50 TORISEL 50 erlotinib Tarceva 50 achieve sustained virologic 50 TKIs 50 AP# [003] 50 HER2 + 50 acromegaly 50 blinatumomab 50 OncoVEX GM CSF 50 HGF 50 tumors GIST 50 lymphoproliferative disorders 50 glioblastoma tumors 49 REVLIMID 49 Li Fraumeni Syndrome 49 ADPKD 49 PCNSL 49 anaplastic thyroid cancer 49 ganetespib 49 TACE 49 relapsed indolent NHL 49 refractory AML 49 Carcinoma 49 chronic HCV infection 49 breast carcinoma 49 Vandetanib 49 CYT# potent vascular disrupting 49 cutaneous squamous cell carcinoma 49 Castration Resistant Prostate Cancer 49 autoimmune hemolytic anemia 49 Taxotere ® 49 TTR amyloidosis 49 XL# [003] 49 Ceflatonin R 49 lung adenocarcinoma 49 dacarbazine 49 Cell Lung Cancer 49 Virulizin ® 49 urothelial bladder cancer 49 proteasome inhibitor bortezomib 49 myeloma cells 49 PARP inhibitor 49 Telintra 49 NOMID 49 elesclomol 49 Acute Lymphoblastic Leukaemia 49 malignant lymphoma 49 cabazitaxel 49 colorectal carcinoma 49 JAK3 49 Rheumatoid Arthritis RA 49 refractory CTCL 49 Kaposi sarcoma 49 adjuvant therapy 49 remission induction 49 biliary tract cancer 49 taxanes 49 myelofibrosis polycythemia vera 49 Velcade 49 ara C 49 basal cell nevus syndrome 49 receptor tyrosine kinase inhibitor 49 prostate tumors 49 Irinotecan 49 trastuzumab Herceptin 49 BRAF inhibitor 49 Multiple Myeloma 49 PTLD 49 VIDAZA 49 ibritumomab tiuxetan 49 refractory acute myeloid 49 glufosfamide 49 S. aureus infections 49 relapsed MM 49 Arzerra ofatumumab 49 bevacizumab 49 medically inoperable 49 prostate cancer HRPC 49 Non Hodgkins lymphoma 49 oxaliplatin 49 B lymphocytes 49 pancreatic cancers 49 refractory PTCL 49 daunorubicin 49 CVP chemotherapy 49 Amigal 49 Lymphomas 49 colon cancer 49 ALK inhibitor 49 pemetrexed 49 XmAb# 49 inoperable pancreatic cancer 49 TEMODAL 49 cediranib 49 amyotrophic lateral sclerosis ALS 49 targeting CD# 49 Gefitinib 49 breast cancers 49 EGFR mutation positive 49 cystic fibrosis CF 49 Genasense 49 Valortim R 49 Nexavar sorafenib 49 ankylosing spondylitis AS 49 IV malignant melanoma 49 nonmelanoma skin cancers 49 neurodegenerative disease 49 myeloproliferative disorders 49 vismodegib 49 refractory colorectal cancer 49 tyrosine kinase inhibitors TKIs 49 chemotherapies 49 Barrett esophagus 49 T#I mutant 49 relapsed acute myelogenous 49 locoregional 49 stage IIIb IV 49 cell chronic lymphocytic 49 myeloproliferative 49 protease inhibitor 49 Novartis Gleevec 49 Waldenstrom Macroglobulinemia 49 complete remissions 49 MELAS 49 talabostat 49 Campath 49 pan HDAC inhibitor 49 cytotoxic 49 phase IIb clinical 49 Zevalin 49 KRAS mutant tumors 49 chronic HBV infection 49 operable breast cancer 49 Dacogen injection 49 ocrelizumab 49 Tarceva erlotinib 49 anti leukemic 49 proteasome inhibitor 49 hormone receptor positive 49 hepatitis C virus 49 Symadex 49 Vectibix monotherapy 49 Acute Leukemia 49 fluoropyrimidine 49 SOD1 49 Metastatic 49 BAY #-# 49 Inflammatory Bowel Disease 49 chronic ITP patients 49 taxane therapy 49 HBeAg negative 49 chemotherapeutic 49 astrocytoma 49 nasopharyngeal carcinoma 49 Ph + 49 secondary hyperparathyroidism 49 refractory Hodgkin lymphoma 49 LymphoStat B 49 AEG# 49 tyrosine kinase inhibitor TKI 49 ulcerative colitis 49 temozolomide 49 NNRTIs 49 sunitinib malate 49 homozygous familial hypercholesterolemia 49 acute myeloid 49 gastrointestinal stromal tumors GISTs 49 immunotherapy 49 molecularly targeted 49 disease modifying 49 cervical carcinoma 49 tyrosine kinase inhibitor 49 Genasense ® 49 oblimersen 49 cholangiocarcinoma 49 autoantibody positive 49 pertuzumab 49 Perifosine 49 Arranon 49 distant metastasis 49 lobular carcinoma 49 IGF 1R 49 autologous stem cell 49 FTY# 49 chemoresistant 49 Proxinium TM 49 JMML 49 relapsing MS 48 Acute Myeloid Leukaemia AML 48 tesmilifene 48 polycythemia vera 48 renal tumors 48 thalidomide Thalomid 48 acute lymphoblastic 48 non Hodgkins lymphoma 48 PRTX 48 androgen independent 48 lung cancers 48 Ph + ALL 48 adverse cytogenetics 48 ACZ# 48 pheochromocytoma 48 carcinoid cancer 48 colorectal tumors 48 chronic hepatitis B. 48 colorectal liver metastases 48 acute myelogenous leukemia 48 metastatic NSCLC 48 Targretin 48 ccRCC 48 squamous cell 48 metastatic CRPC 48 Myelodysplastic Syndromes 48 Cetuximab 48 basal cell carcinoma 48 Romidepsin 48 Renal cell carcinoma 48 Revlimid lenalidomide 48 EGFR expressing 48 low dose cytarabine 48 allogeneic transplantation 48 prognostic variables 48 Nuvion 48 osteosarcomas 48 Cytoxan 48 activating mutations 48 acute ischemic stroke 48 Friedreich Ataxia 48 refractory CML 48 rheumatoid arthritis 48 sunitinib Sutent 48 AAV2 48 Marqibo 48 castration resistant 48 non squamous 48 cancer 48 mTOR inhibitor 48 CaP 48 sarcomatoid 48 Plicera 48 Voreloxin 48 metastatic colorectal 48 GW# [003] 48 immunosuppressant 48 FOLFOX chemotherapy 48 stage IIIA 48 myeloproliferative diseases 48 lung cancer 48 tivozanib 48 inherited neurodegenerative disorder 48 Triapine 48 antitumor activity 48 allogeneic stem cell 48 cyclophosphamide FC 48 oral mucositis 48 micafungin 48 Chronic Myelogenous Leukemia 48 nonmelanoma skin cancer 48 BMN 48 psoriasis 48 Hodgkin Disease 48 transthyretin amyloidosis 48 Sutent sunitinib 48 monoclonal antibody therapies 48 hormone deprivation 48 docetaxel Taxotere R 48 juvenile idiopathic arthritis JIA 48 Omacetaxine 48 allergic asthma 48 galiximab 48 papillary renal cell carcinoma 48 carboplatin paclitaxel 48 Myelodysplastic syndromes MDS 48 myeloablative 48 HoFH 48 chemoresistance 48 pralatrexate 48 Hsp# inhibition 48 distant metastases 48 mycophenolate mofetil 48 EGFR TKI 48 MGCD# [001] 48 BRAF gene 48 Annamycin 48 metastatic lesions 48 bosutinib 48 osteosarcoma 48 HuMax CD# 48 NNRTI resistance 48 myelofibrosis MF 48 MabThera Rituxan 48 ALD# 48 squamous cell cancer 48 clinically localized prostate 48 gemcitabine carboplatin 48 huN# DM1 48 FluCAM 48 invasive aspergillosis 48 fulvestrant 48 lenalidomide Revlimid R 48 Vidofludimus 48 aHUS 48 Melanoma 48 PI3K inhibitors 48 Hodgkin disease 48 ON #.Na 48 malignant transformation 48 ISEL 48 Exelixis XL# 48 nonsquamous histology 48 Glioblastoma multiforme GBM 48 eosinophilic asthma 48 lupus 48 untreated CLL 48 HBV infection 48 systemic fungal infections 48 Cell Lymphoma 48 adecatumumab 48 tanespimycin 48 hA# 48 BR.# 48 de novo AML 48 NMIBC 48 Merck KGaA Erbitux 48 neuroendocrine cancers 48 chronic hepatitis C 48 docetaxel Taxotere ® 48 NF1 48 free survival PFS 48 eltrombopag 48 imetelstat 48 KRAS mutant 48 HBeAg negative chronic hepatitis 48 prostate cancer PCa 48 olaparib 48 antibody MAb 48 Lapatinib 48 Arzerra 48 etoposide 48 voreloxin 48 IDH1 mutation 48 VELCADE 48 lenalidomide 48 IRESSA 48 Chronic Myelogenous Leukemia CML 48 astrocytomas 48 CD# mAb 48 Gorlin syndrome 48 radiation sensitizer 48 HCV SPRINT 48 INGN 48 KRAS mutation 48 adenocarcinomas 48 posaconazole 48 FSGS 48 relapsed 48 cell lymphoma PTCL 48 BRAF mutations 48 entinostat 48 hypereosinophilic syndrome 48 micrometastases 48 Cloretazine 48 HQK 48 SSc patients 48 dimebon 48 Evoltra TM 48 ovarian cancers 48 regorafenib 48 Revlimid 48 stage IIIb 48 imatinib resistance 48 Metastatic breast cancer 48 baminercept 48 carboplatin 48 FOLOTYN 48 TNF inhibitors 48 MAGE A3 48 invasive fungal infections 48 idiotype vaccine 48 diagnosed multiple myeloma 48 EoE 48 Etanercept 48 prior chemotherapy regimens 48 Malignant Melanoma 48 P. aeruginosa 48 gemcitabine Gemzar ® 47 refractory 47 chronic plaque psoriasis 47 alvespimycin 47 malignant lymphomas 47 subependymal giant cell 47 INCB# [002] 47 irinotecan 47 squamous cell cancers 47 eculizumab 47 infliximab 47 cytoreductive nephrectomy 47 INCB# [001] 47 relapsed follicular 47 PAH 47 chemotherapy 47 resectable 47 palifosfamide 47 Ceftaroline 47 interferon therapy 47 acute GvHD 47 Cell Lymphoma CTCL 47 cholinesterase inhibitors 47 Glioblastoma Multiforme GBM 47 prostate tumor 47 invasive fungal infection 47 juvenile myelomonocytic leukemia 47 monotherapy 47 SJIA 47 bladder carcinoma 47 SCH # 47 vWF 47 PEP# [003] 47 5FU 47 ER CHOP 47 BiovaxID 47 relapsed refractory aggressive 47 AMN# [001] 47 localized prostate cancer 47 lymphocyte 47 Testicular cancer 47 irinotecan chemotherapy 47 Halaven 47 trastuzumab Herceptin ® 47 Golimumab 47 tamibarotene 47 atypical Hemolytic Uremic Syndrome 47 Omnitarg 47 refractory metastatic 47 Enzastaurin 47 autologous transplants 47 Daclizumab 47 seliciclib 47 achieved sustained virological 47 refractory metastatic colorectal cancer 47 grade cervical intraepithelial 47 lung carcinomas 47 allogeneic bone marrow 47 Soft Tissue Sarcoma 47 CLL8 47 MLL AF9 47 myeloid leukemia 47 neoadjuvant therapy 47 histone deacetylase HDAC inhibitor 47 Lenalidomide 47 curative therapy 47 sJIA 47 Campath ® 47 ulcerative colitis UC 47 epithelial tumors 47 oligodendrogliomas 47 Hedgehog pathway 47 VEGF inhibitors 47 bortezomib Velcade 47 CML 47 panitumumab Vectibix 47 seropositive patients 47 TRISENOX 47 Carfilzomib 47 HDAC 47 Cotara 47 Quinamed 47 HDAC inhibitors 47 VFEND 47 anthracycline taxane 47 tigecycline 47 HspE7 47 hypophosphatasia 47 NAFLD 47 Non Hodgkin Lymphomas 47 Surgical resection 47 PegIFN RBV